Skip to main content
Clinical Trials/CTRI/2026/01/100942
CTRI/2026/01/100942RecruitingPhase 4

A Single-Center, Randomized Study Comparing High Pressure Balloon and Cutting Balloon for In-Stent Restenosis (ISR) Treatment: Evaluation of Stent Expansion Using OCT Imaging

SIS Medical AG1 site in 1 country100 target enrollmentStarted: January 24, 2026Last updated:

Trial Snapshot

Phase
Phase 4
Status
Recruiting
Sponsor
Enrollment
100
Locations
1
Primary Endpoint
Stent expansion ratio as assessed by OCT at the end of the procedure. Stent expansion will be calculated as the minimal stent area (MSA) achieved post-treatment, compared to the reference vessel diameter.

Study Overview

Brief Summary

Treating in-stent restenosis (ISR) by percutaneous coronary intervention (PCI) is still a challenging approach for there is a substantial (up to 20%) risk of procedural complications and recurrent restenosis (target lesion failure, or TLF) after PCI. In particular, one of the primary causes of ISR has been found to be stent underexpansion. One of the best indicators of results following PCI of ISR in this situation is luminal gain. But underlying calcifications frequently impede luminal gain and ideal stent expansion.

The study device, OPN™ balloon (SIS Medical, Fauenfeld, Switzerland) is a twin layer and highly non-compliant balloon (NCB), which can be used at very high-pressures (burst pressure rate up to 35 atm). Several reports have described its benefits in “undilatable” and highly calcified native coronary lesions. In cases with ISR, correction of stent under-expansion and neointimal compression by using the OPN™ NCB could lead to increased luminal gain and thus improved clinical outcomes. However, physicians are often afraid of aggressive dilatation applying high-pressures (e.g. > 25 atm) for treatment of heavily calcified lesions since they fear periprocedural complications, especially vessel dissections and perforations. We have previously describe the use of the OPN™ NCB in a small population of patients with ISR treated with a bioresorbable scaffold. But the safety and utility of this balloon device has not been systematically evaluated in a large all-comer ISR population yet.

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
None

Eligibility Criteria

Ages
18.00 Year(s) to 99.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Patients presenting with in-stent restenosis (ISR) in coronary arteries requiring revascularization for percutaneous coronary intervention (PCI).Patients or a legally authorized representative must provide written informed consent to participate in the study.Patients with angiographically confirmed ISR in a previously implanted coronary stent, Suitable for OCT imaging.

Exclusion Criteria

  • Severe left ventricular dysfunction (ejection fraction less than 30%).
  • History of a stroke or transient ischemic attack (TIA) within 7 days, or any prior intracranial haemorrhage.
  • Concurrent participation in another clinical study.

Outcomes

Primary Outcomes

Stent expansion ratio as assessed by OCT at the end of the procedure. Stent expansion will be calculated as the minimal stent area (MSA) achieved post-treatment, compared to the reference vessel diameter.

Time Frame: At Baseline, 1 Month

Secondary Outcomes

  • Procedural Success.(Procedural Complications.)

Investigators

Sponsor
SIS Medical AG
Sponsor Class
Other [Medical Device Manufracturer]
Responsible Party
Principal Investigator
Principal Investigator

Dr Praveen Chandra

Medanta- The Medicity

Study Sites (1)

Loading locations...

Similar Trials